Search

The enthusiasm for Moderna and MSD's personalized mRNA vaccine against melanoma has led to a notable increase in the company's market capitalization, despite the fact that the results have not yet been fully presented and experts warn about the limitations of its effectiveness in other types of cancer. (translated)

Moderna and Merck announced sensational results from the third phase of clinical trials of mRNA therapy for cancer, which statistically significantly prolonged the time without disease recurrence and distant metastases, marking them as pioneers in the development of vaccines for melanoma. (translated)

The personalized mRNA vaccine, developed in collaboration between Moderna and Merck, has achieved a significant breakthrough in the treatment of melanoma, as it helps the immune system recognize cancer cells after surgery and reduces the risk of disease recurrence, as demonstrated by a successfully completed phase three clinical trial. (translated)

Pharmaceutical companies MSD and Moderna have announced positive results from a clinical trial of a personalized therapeutic vaccine aimed at reducing the risk of relapse in melanoma patients, although they have not yet provided specific details about the efficacy of the therapy combined with immunotherapy, which has driven up their stock value. (translated)

The article discusses the promising results of a study on vaccines for the treatment of melanoma, one of the most aggressive types of skin cancer, and features the participation of researchers Bruno Sarmento and Paula Videira, raising the question of whether this could be the path to a cure for the disease. (translated)

The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw #mRNAvaccine #CancerResearch #Immunotherapy #Nospecificcountrycodesarementionedinthetweet.

An experimental mRNA vaccine developed by Merck and Moderna could significantly reduce the risk of melanoma recurrence, one of the most aggressive forms of skin cancer, showing promising results in clinical trials involving over 1,000 patients and set to be evaluated for approval by the competent authorities in a few months. (translated)

Moderna and Merck announced successful results from the Phase III study of their personalized mRNA vaccine for melanoma in combination with the immunotherapy Keytruda, which could mean a revolution in cancer treatment by tailoring therapy to the genetic profile of the tumor, although detailed data from studies and regulatory approval are still lacking. (translated)

‼️Breaking:‼️ Ein personalisierter, therapeutischer mRNA Impfstoff gegen schwarzen Hautkrebs/Melanom. Der Beginn dieser Forschung war vor über 10 Jahren; nun werden wir vielleicht ab 2027 eine sehr effektive Behandlung gegen Melanome haben. mRNA ist ein Segen! Und an alle Impfschwurbler, Antivaxxer und Wissenschafts-Allergiker: 🖕🖕🖕‼️ Studie: https://t.co/0fMC1vdYcO @moderna_tx @Merck @SZ (Foto) #mRNA #Krebsforschung #Impfung

Moderna and Merck laboratories announced promising results of a personalized vaccine against relapses of skin cancer, offering new hope to patients with melanoma, according to oncologist Suzette Delaloge, who emphasizes the importance of this advance and the anticipation of detailed data to come. (translated)

Moderna and Merck have announced an important discovery in cancer vaccine research, demonstrating the effectiveness of an experimental mRNA vaccine called Intismeran in combination with the immunotherapy Keytruda for the treatment of melanoma, the most aggressive type of skin cancer. (translated)

VACCINE AGAINST CANCER, MADE FROM TUMOR In a regular vaccine, we all receive the same active ingredient. In the new melanoma treatment, it is just the opposite: a special vaccine is made for each patient from data about their tumor. The process begins after surgery. From the removed tumor (translated)

The experimental vaccine against melanoma, announced by Moderna and Merck after passing a clinical trial, generates excitement in the medical community for its potential as a historic advancement, although caution is also expressed due to the lack of detailed data on its effectiveness. (translated)